NCT04608149

Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

Carpediem(TM) Post Market Surveillance Study

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 36 (actual)
• Sponsor: Mozarc Medical US LLC · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription. A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem™ system, will be invited to participate in the study. After obtaining institutional review board approval and written informed consent from a parent or legally authorized representative (LAR), data from all subjects treated with the Carpediem™ system will be included in the study. A minimum of 35 subjects will be enrolled and sites may be asked to screen and enroll patients for the study for up to 36 months. Status of subjects discharged from hospital will be collected at 30- and-90 days following hospital discharge by phone interviews in accordance to local standard of care practices, review of in-hospital records or in-clinic visit, as available.

Detailed description

The post market surveillance study is designed to capture data in the real-world clinical setting on the use of the Carpediem™ system and will evaluate the safety and performance in children requiring CRRT in the US. Data on survival and the effectiveness of the Carpediem™ system on renal function recovery will be evaluated. A comprehensive evaluation of subjects being treated with Carpediem™ will include, but is not limited to, acuity at hospital/ICU admission and prior to CRRT initiation, Carpediem™ treatment parameters, laboratory data, and requirement for mechanical ventilation and/or inotropic support. Subject status and requirement for renal replacement therapy post hospital discharge will be evaluated at 30- and 90-days.

Conditions

• Acute Kidney Injury
• Fluid Overload

Interventions

Type	Name	Description
DEVICE	Carpediem System	Continuous renal replacement therapy

Timeline

• Start date: 2021-01-20
• Primary completion: 2026-04-01
• Completion: 2026-04-01
• First posted: 2020-10-29
• Last updated: 2026-04-01

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated device study